KIDNEY INJURY DURING TREATMENT WITH AFLIBERCEPT VERSUS RANIBIZUMAB
Intravitreal aflibercept and ranibizumab carry comparable risks of renal adverse events despite their distinct systemic pharmacodynamics.
Authors
- Michael A. McIsaac (ORCID: https://orcid.org/0000-0002-5273-5450)
- Sudeep S. Gill (ORCID: https://orcid.org/0000-0001-9292-1197)
- Chaim M. Bell (ORCID: https://orcid.org/0000-0002-3778-9469)
- Jonas Shellenberger (ORCID: https://orcid.org/0000-0002-8676-6650)
- J. Michael Paterson (ORCID: https://orcid.org/0000-0001-5995-1714)
- Marlo Whitehead (ORCID: https://orcid.org/0000-0002-0580-437X)
- Sherif El-Defrawy (ORCID: https://orcid.org/0000-0002-7678-9947)
- Susan E. Bronskill (ORCID: https://orcid.org/0000-0002-7341-0655)
Institutions
- Providence Health Care (CA)
- University of Toronto (CA)
- Queen's University (CA)
- University of Prince Edward Island (CA)
- Hotel Dieu Hospital (CA)
- Kensington Health (CA)
- Sinai Health System (CA)
- Kingston Health Sciences Centre (CA)
- Sunnybrook Hospital (CA)
- Sunnybrook Research Institute
- McMaster University (CA)
Publication Details
- Journal
- Retina
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1097/iae.0000000000004653
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00